Conference Coverage
Latest News
Circulating Tumor DNA Hints at BC Recurrence Risk
Despite suggestive results, researchers say it’s too early to use ctDNA for adjuvant decisions in early, high-risk breast cancer.
Feature
Greater Transparency of Oncologists’ Pharma Relationships Needed
Reducing industry payments to hematologists and oncologists could benefit patients, say experts.
Conference Coverage
Cognitive Decline Minimal After Endocrine + CDK4/6 Inhibition in BC
Authors investigate cognitive functioning in the same cohort used in the SONIA trial and a matched control group of individuals that did not have...
Conference Coverage
‘Double-Expresser’ DLBCL: Tucidinostat Improved R-CHOP Outcomes
As of yet, there’s been no improvement in overall survival with tucidinostat in an interim analysis of a Chinese phase 3 trial.
Conference Coverage
ASCO 2024: An Expert’s Top Hematology Highlights
Chief science officer at American Cancer Society pinpoints practice-changing blood cancer research that emerged at this year’s conference.
Conference Coverage
Eribulin Similar to Taxane When Paired With Dual HER2 Blockade in BC
Patients with HER2-positive, locally advanced or metastatic breast cancer who cannot tolerate the standard taxane-based regimen have a new option...
Conference Coverage
PFS Benefits Seen With Palbociclib + Endocrine Therapy in Breast Cancer
Palbociclib plus endocrine therapy or chemotherapy: Which is best in HR+/HER2- metastatic breast cancer?
Feature
New ADC results mixed in metastatic breast cancer
While T-DXd showed promise for yet another indication at ASCO, other findings underscored that much still remains to be learned about this drug...
Conference Coverage
Adjuvant Avelumab Benefits Seen in High Risk, Triple Negative BC
Researchers conduct first randomized phase 3 trial of patients with TNBC treated with adjuvant avelumab.
Conference Coverage
Clinical Controversy: Standard Dose or Baby TAM for Breast Cancer Prevention?
Docs debate which dose of tamoxifen is best for reducing breast cancer risk at the ESMO Breast Cancer Congress.
Conference Coverage
New Tools for Monitoring Multiple Myeloma
“The detection of this minimal residual disease corresponds with a significant reduction in survival,” according to an expert from the University...